

DAFTAR PUSTAKA

1. Albright F, Smith PH, Richardson AM. (1941). Post-menopausal osteoporosis. *Trans Assoc Am Physicians*; 116(22):2456-2474.
2. Andini, IF. (2015). Perbedaan Densitas Mineral Tulang Wanita Premenopause Pengguna Kontrasepsi Berbasis Hormonal dan Tidak Hormonal. Program Pasca Sarjana Magister Kebidanan UNAND.
3. Bell, NH. (2003). RANK ligand and the regulation of skeletal remodeling. *J Clin Invest*; (111):1120-22.
4. BKKBN. (2014). Pelayanan Kontrasepsi. Jakarta: Badan Kependudukan dan Keluarga Berencana Nasional Direktorat Pelaporan dan Statistik.
5. Brooks M. (2013). FDA Okays New Extended-Regimen Oral Contraceptive. *Medscape Medical News*.
6. Civitelli R, Villareal RA, Napoli N. (2009). Bone turnover markers: understanding their value in clinical trials and clinical practice. *Osteoporos Int*; 20: 843-851.
7. Clark MK., Soves M., Levy BT, Tenhundfeld P. (2001). Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. *Fertil Steril*; 75(5): 871-7
8. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, Debanne SM. (2005). Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. *Am J Obstet Gynecol*; 192:42-47.
9. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. *Contraception* 65(1), 21–27 (2002).
10. Cundy T, Ames R, Horne A, Clearwater, Roberts H, Gamble G, Reid IR. (2009). A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. *J Clin Endocrinol Metab*; 88:78-81.
11. Cundy T., Evans M., Roberts H, Wattie D, Ames R, Reid IR. (1991). Bone density in women receiving depot medroxyprogesterone acetate for contraception. *British Medical Journal* 303:13-16.

12. Cundy T., Cornish J., Evans M.C. Reid R. (1994). Recovery of bone density in women who stop using medroxyprogesterone acetate. *British Medical Journal* 308:247-248.
13. Cunningham.G., Leveno R.J., Bloom S.I. et al. (2013). *Obstetri Williams*. Jakarta : EGC
14. Czerwinski E, Badurski JE, Marcinowska S.E, Osieleniec J. (2007). Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. *Ortop Traumatol Rehabil.* 9(4):337-56.
15. D' Arcangues C. (2007) WHO statement on hormonal contraception and bone health. *Contraception*:75:S2.
16. Dinas Kesehatan Kota Padang. (2014). *Profil Kesehatan Sumatera Barat*.
17. Dinas Kesehatan Kota Padang. (2013). *Profil Kesehatan Sumatera Barat*.
18. Dillis CL. (2003). Change in mammographic breast density associated with the use of depo-provera. *The Breast Journal*: volume 9(4) : 312-315.
19. Diza. Miranda. (2008). Perbandingan Densitas Mineral Tulang pada Pemakaian Kontrasepsi kombinasi dan DMPA untuk Jangka Panjang di Puskesmas Mandala Medan. *Bagian Obstetri dan Ginekologi FK USU*.
20. Everett, S. (2004) *Handbook of Contraception and Reproductive Sexual Health*. Ed.2. Elsevier;168-180.
21. Ferri FF.(2016). Ferri's Clinical Advisor 2016. Elsevier; 907-909.e3.
22. Fraser & Cooper. (2011). *Buku Ajar Bidan Myles*. Jakarta : EGC.
23. Gary SF . (2013). Kelley's Textbook of Rheumatology. Ed. 9. Elsevier Inc; 160-179.
24. Gbolade B, Ellis S, Murby B, Randall S, Kinkman R. (1998) Bone density in long term users of depot medroxyprogesterone acetate. *Obstet Gynaecol*: 105 (7).
25. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. (2002). Production and actions of estrogens. *N Engl J Med.* 346(5):34052.
26. Guyton A. (2012). *Fisiologi kedokteran*. Edisi ke-11. Jakarta: EGC.
27. Hare Z, Jhonson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. (2010). Recovery of bone mineral density in adolescents following the use of

depot medroxyprogesterone acetate contraceptive injections. Elsevier; 81(4) : 281-291.

28. Herrmann M, Seibel MJ.(2010) The effects of hormonal contraceptives on bone turnover markers and bone health. *Clinical Endocrinology (Oxford)*;72, 571-583.
29. Kaunith AM, Miller PD, Rice PD, Ross D, Mc Clung MR.(2006). Bone mineral density in women aged 25-35 years receiving depot *medroxyprogesterone* acetate: recovery following discontinuation. Elsevier: 74(2) : 90-9.
30. Kaunitz AM.(2005). DMPA, Bone Moneral Density and Teens: Recent and Reassuring Data. *Medscape Obgy/Gyn*;10(1).
31. Khosla S, Oursler MJ, Monroe DG.(2012). *Trend Endocrinol Metab. Nasional Institutes of Health (NIH)*;(11):576-581.
32. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. (1976). Long-term prevention of postmenopausal osteoporosis by oestrogen. *Lancet* i:1038–1040.
33. Loran SC. (2015). C- Terminal Telopeptide. American College of Physicians.
34. McKinley Health Center. (2008). DepoProvera® (DMPA) Contraceptive Injection Patient Information. *Journal of Illions University at Urbana Champaign*, 026, 1-2.
35. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eshenbach DA.(2000) Depomedroxyprogesterone-induced Hypoestrogenism and Change in Vaginal Flora and Epithelium. *Am J Obstet & Gynecol*; 96:431-9.
36. Monroe DG, Secreto FJ, Spelsberg TC.(2003). Overview of estrogen action in osteoblasts: Role of the ligand the receptor and the co-regulators. *J Musculoskel Neuron Interact*;3(4):357-62.
37. Nelson L.A.(2010). Battered and Bruised but Still Needed and Used in the USA. *Expert Rev of Obstet Gynecol*;5(6):673686.
38. Pusat Data dan Informasi. (2014). *Situasi dan Analisis Keluarga Berencana. Kementrian Kesehatan RI, Jakarta.*
39. Puspitawati I, Indarwati, Sukorini U, Erlina, Herowati P.(2013). Higher Level of CTX in Osteoporotic Women Compared to Normal an Osteopenic Women. *Medical Clinical Pathology and Medical Laboratory*; 19 (1).
40. Razali R. R.(2008). Kadar Estradiol Serum Pada Pemakaian KB DMPA 1 Tahun dan 3 Tahun. *Bagian Obstetri dan Ginekologi FK USU.*

41. Ryan PJ, Singh SP, Guillebaud J.(2002). Depot medroxyprogesterone and bone mineral density. *The Journal of Family Planning & Reproductive health care*; 28 (1) :12-15.
42. Sastroasmoro, Sudigdo. & Sofyan Ismael. (2002). *Dasar- dasar Metodologi Penelitian Klinis*. Edisi ke-2.Jakarta. Sagung Seto.
43. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM.(2005). Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. *Arch Pediatr Adolesc Med*;159:139-144.
44. Sherwood, L. (2012). *Fisiologi Manusia dari Sel ke Sistem*. Edisi 6. Jakarta. EGC
45. Stoppard, M.(2011). *Famili Health Guide*.Jakarta : Erlangga ; Hal :422-425.
46. Shlomo, M.(2011). *Williams Textbook of Endocrinology*, Twelfth Edition. Elsevier Inc; 661- 687.
47. Techy, F.(2012). CHAPTER 15 Bone Modeling and Remodeling. *Spine Surgery: Techniques, Complication Avoidance and Management*; 139-144.
48. Theoleyre S, Wittrant Y, Kwan Tat S, Forton Y, Redini F, Heymann D.(2004). The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. *Cytokine Growth Factor Rev*; 15:457–475.
49. Thomas SDC. (2012). Bone turnover markers. *Aust Prescr*; 35: 156-158
50. Watson CS, Jeng YJ, Kochukob MY.(2008) Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. *NCBI*; 2:3326-3336.
51. Yudaniayanti IS.(2005). Aktifitas alkaline phosphatase pada proses kesembuhan patah tulang femur dengan terapi CaCO₃ dosis tinggi pada tikus jantan. *Media Kedokteran Hewan*; 21(1): 15-18.